| 2.31 -0.22 (-8.7%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.27 | 1-year : | 3.81 |
| Resists | First : | 2.79 | Second : | 3.27 |
| Pivot price | 2.29  |
|||
| Supports | First : | 1.96 | Second : | 1.45 |
| MAs | MA(5) : | 2.55  |
MA(20) : | 2.14 |
| MA(100) : | 1.54 |
MA(250) : | 1.41 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 72.3 |
D(3) : | 80.6 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 2.79 | Low : | 0.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALLO ] has closed below upper band by 49.0%. Bollinger Bands are 197.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 22 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.5 - 2.52 | 2.52 - 2.53 |
| Low: | 2.25 - 2.27 | 2.27 - 2.28 |
| Close: | 2.28 - 2.31 | 2.31 - 2.33 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Wed, 04 Mar 2026
Insider Selling: Allogene Therapeutics (NASDAQ:ALLO) SVP Sells 7,132 Shares of Stock - MarketBeat
Tue, 03 Mar 2026
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen - Yahoo Finance
Mon, 02 Mar 2026
Cancer CAR T firm Allogene sets March 12 call on 2025 results - Stock Titan
Mon, 02 Mar 2026
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update - GlobeNewswire
Sat, 28 Feb 2026
Primecap Management Co. CA Has $8.78 Million Stock Position in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Fri, 27 Feb 2026
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 225 (M) |
| Shares Float | 156 (M) |
| Held by Insiders | 16.6 (%) |
| Held by Institutions | 65.3 (%) |
| Shares Short | 18,820 (K) |
| Shares Short P.Month | 18,080 (K) |
| EPS | -0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.4 % |
| Return on Equity (ttm) | -54.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.75 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -158 (M) |
| Levered Free Cash Flow | -84 (M) |
| PE Ratio | -2.36 |
| PEG Ratio | 0 |
| Price to Book value | 1.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|